Genia Long

Education

M.P.P., Harvard University

Summary of Experience

Ms. Long is an expert in the life sciences industry, with particular expertise in the economics, public policy, and business strategy of innovation. She has over 25 years of experience consulting to clients on topics such as time-sensitive and high-stakes policy issues for companies and trade groups, and asset-specific launch and optimization strategies across all major therapeutic areas. Her work spans a wide variety of issues affecting the biopharmaceutical industry, including intellectual property protection; R&D economics; the financing of drug innovation; and the evolving landscape of branded competition, generic entry, and biosimilars. Ms. Long has also advised on the potential impacts of Inflation Reduction Act provisions on the biopharmaceutical market, the commercial importation of prescription drugs, and payer and manufacturer challenges associated with transformative therapies such as gene therapy. Her work has been published in peer-reviewed journals such as Health Affairs, Nature Reviews Drug Discovery, The American Journal of Managed Care, the Journal of Medical Economics, and PharmacoEconomics.